We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New AI Tool Outperforms Previous Methods for Identifying Colorectal Cancer from Tissue Sample Analysis

By LabMedica International staff writers
Posted on 03 Mar 2025

Tissue analysis typically involves a pathologist reviewing scanned digital slides from a patient’s intestinal sample and marking specific areas, such as those where cancerous and related tissues are present. More...

A new artificial intelligence (AI)-driven tool has now been developed to identify colorectal cancer in tissue samples that surpasses all previous models in terms of classification accuracy.

This tool was the result of a collaborative study led by researchers at the University of Jyväskylä (Jyväskylä, Finland). The AI model created in this study demonstrated superior performance in classifying tissue samples compared to prior models. This new tool has the potential to streamline the process for doctors by automating the analysis of tissue slides. It analyzes samples and highlights areas with various tissue types, offering a level of accuracy that could greatly reduce the workload of histopathologists, leading to faster diagnoses, prognoses, and clinical insights.

The research team has made this AI tool publicly available to promote further research and collaboration. While the results are promising, the team emphasizes that the integration of AI tools into clinical practice should be approached cautiously. For AI solutions to become standard in clinical settings, they must undergo a thorough validation process to ensure that they meet both clinical and regulatory standards.

"Based on our study, the developed model is able to identify all tissue categories relevant for cancer identification, with an accuracy of 96.74%," said Fabi Prezja, the researcher responsible for designing the method. "The free availability aims to accelerate future advances by encouraging scientists, developers and researchers worldwide to continue developing the tool and finding new applications for it."

Related Links:
University of Jyväskylä


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.